更多招聘信息请关注BioArt人才账号
BioArt人才
瑞士EPFL 唐力组招收NCCR 博士后
Introduction
Starting Early 2027 | EPFL & CHUV, Lausanne, Switzerland
Afull-time postdoctoral position is available starting January 2027in the Tang Lab (tang-lab.epfl.ch) at EPFL and the Francesco Ceppi Group (Ceppi) at Lausanne University Hospital (CHUV), within the Swiss National Centre of Competence in Research NCCR Children & Cancer (WP4: Developing immune-based approaches for childhood cancers). The successful candidate will join a highly collaborative, multidisciplinary project involving the Tang, Ceppi, and other groups of the NCCR project, with the overarching goal of developing new strategies to overcome CD19 CAR-T cell therapy failure in pediatric leukemia. The project is funded for four years and will focus on understanding and overcoming mechanisms of resistance and relapse following CAR-T cell therapy.
Project Overview and NCCR Children & Cancer
The project will investigate whetherCAR-T cells with cross-type immune coordinationcan enhance therapeutic efficacy and prevent leukemia relapse. The underlying mechanisms responsible for this potential improvement will be systematically investigated.
In parallel, the project will aim to identifynovel therapeutic targets and antigen combinationsfor pediatric acute lymphoblastic leukemia (ALL), with the ultimate goal of developing next-generationdual- or multi-antigen CAR-T cell therapies.
TheNCCR Children & Cancerestablishes a national Swiss framework addressing the unique challenges of childhood cancer by bringing together cutting-edge expertise spanning fundamental research, clinical translation, data science, artificial intelligence, communication science, and patient and nursing perspectives.
The consortium brings together leading Swiss researchers and clinicians working on pediatric leukemia, brain tumors, neuroblastoma, sarcomas, functional oncogenomics, and computational approaches to cancer research.
Tang Lab–EPFL
The Tang Lab at EPFL focuses on developing innovative strategies to engineer multidimensionalimmunity–diseaseinteractions, an emerging field referred to as immunoengineering.
The laboratory investigates howmetabolic, chemical, and mechanical cuescan be manipulated to improve the safety and efficacy of cancer immunotherapies, with a particular emphasis on engineering immune-cell function for therapeutic applications. For more information, please see our website (tang-lab.epfl.ch).
Ceppi Group – CHUV
TheCeppi Group at CHUVhas longstanding expertise inpediatric oncology and cellular therapiesand leads thePediatric Platform for Immunotherapy & Cell Therapy (PEPITE).
The group is committed to advancing translational research aimed at developing and ultimately delivering innovative cellular therapies for children withrelapsed or refractory pediatric malignancies. For more information, please visit the CHUV Pediatric Hematology-Oncology research website or contactDr. Francesco Ceppiat E-mail.
The Postdoctoral Position
The postdoctoral researcher will beco-supervised by Prof. Li Tang (EPFL) and Dr. Francesco Ceppi (CHUV)and will work at the interface between immunoengineering, cancer biology, and pediatric oncology.
The main objectives of the project will include:
Engineering CAR-T cellswith synergistic type 1 and type 2 immune functions and evaluating their therapeutic activity.
Investigating the potential ofengineered CAR-T cellsto prevent resistance and relapse of leukemia.
Assessing CAR-T cell efficacy and mechanisms of action inmouse models.
Performing thepreclinical evaluation of human CAR-T cellsusing patient-derived models.
Systematically identifyingnovel therapeutic targets and antigen combinationsfor pediatric ALL.
Developing and evaluatingdual- and multi-antigen CAR-T cell strategies.
Investigating howmetabolic modulation of immune cellscan influence CAR-T cell function and therapeutic efficacy.
Establishing close collaborations with clinicians at CHUV to facilitate the translation of new immunotherapeutic approaches toward clinical application.
The candidate will have the opportunity to work in a highly interdisciplinary environment, combiningcell engineering, cancer immunology, molecular biology, functional genomics, preclinical models, and translational pediatric oncology.
The position offers the opportunity to contribute to an ambitious, clinically oriented research program addressing major challenges inCAR-T cell therapy for childhood leukemia, while working closely with both researchers and clinicians.
The working language is English.
The salary and benefits areinternationally competitive for postdoctoral researchers at EPFL and CHUV.
Requirements:
The candidates are expected to have strong expertise and experimental background in immunology, cancer immunotherapy, immune metabolism, mouse studies, and patient-derived models.
Being willing to work in a highly interdisciplinary environment.
Having track-record in publishing peer-reviewed journal articles asthe first author in tier 1 journals
Being self-motivated.
Having good communication skills (writing and speaking in English).
Responsibilities:
Take the lead of the project and prepare regular reports
Publish research resultsin tier 1 journals
Assist PIS in grant writing
Present data at conferences and lab meetings
Help PI on leading the organization and maintenance of the lab
Train junior lab members
How to apply
We will begin reviewing applications immediately and will continue until the position is filled. Priority will be given to applications received before15thNovember 2026.
Step 1: Interested postdoc candidates please apply by filling the Google form using the link:
https://docs.google.com/forms/d/e/1FAIpQLSea1-rYi9_VIeWPVTE9iUnBww8ZBzxDHHssmvdgfW82lwfZig/viewform
Step 2: After filling the Google form, please send an email (Subject: Application for a NCCR Postdoctoral Position-[Your name]) attaching your curriculum vitae, a cover letter, and the names of three referees to:
Dr. Francesco Ceppiat E-mail.
Prof. Li Tangat E-mail.
EPFL | École polytechnique fédérale de Lausanne
Highly ranked worldwide, EPFL is one of the only two federal universities in Switzerland. It is also one of Europe’s most vibrant and cosmopolitan science and technology institutions. See EPFL in YouTube: Welcome to EPFL - 2017. EPFL offers an exceptional research and training environment with state-of-the-art facilities. Laboratory of Biomaterials for Immunoengineering (Tang lab @ EPFL) is located on the 2nd floor of the new MED building. You can have a virtual lab visit here: ME&MEDàMenuàLaboratory of Biomaterials for Immunoengineering (Tang).
CHUV | Centre hospitalier universitaire vaudois
TheCHUVis located in the heart of the Leman Lake “Health Valley”, around Lausanne, a charming city on Leman Lake. Since 2019, our hospital has been ranked among the top best hospitals in the world, according to the US magazine Newsweek. The CHUV is one of five Swiss academic public health care centers, and plays a leading role in the fields of medical care, research, teaching and training, in collaboration with the Faculty of Biology and Medicine at the University of Lausanne. The new Children’s Hospital opens on 14 May 2025 with the completion of a complex building project that started in 2019 in the heart of the Lausanne hospital complex (Opening of the new CHUV Children’s Hospital: A historic milestone in paediatric medicine - Lausanne University Hospital). (Immunotherapy for children - Lausanne University Hospital)
申请方式
投递简历请选择：瑞士EPFL 唐力组招收NCCR 博士后
简历投递方式（可选任一）：
1. 扫描二维码投递简历；
3. 点击链接投递简历：https://data.bioart.com.cn/f/p0EB2y（复制链接至浏览器投递简历）
课题组招聘广告请发送至：bioarthr@bioart.com.cn
制版人：半夏
